Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > FGF-21

FGF-21

Brief Information

Name:Fibroblast growth factor 21
Target Synonym:FGF21
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Phase 3 Clinical

Licensing

Project Name Modality Therapeutic Area Indications Stage Right Available
GIP/GLP-1/FGF21 Fusion Protein treating NASH, T2DM, Hyperlipoidemia NASH, T2DM, Hyperlipoidemia Preclinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CHEK-ATF163-Cell-based assay
 FGF-21 FACS

Expression analysis of human Klotho beta on Human FGF-21 (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human FGF-21 (Luc) HEK293 Reporter Cell or negative control cell using anti-human Klotho beta antibody followed by staining with PE anti-human IgG antibody.

Synonym Name

FGF-21, FGF21

Background

Fibroblast growth factor 21 (FGF21), which stimulates glucose uptake in differentiated adipocytes via the induction of glucose transporter SLC2A1/GLUT1 expression. FGF21 has been shown to protect animals from diet-induced obesity when overexpressed in transgenic mice. It also lowers blood glucose and triglyceride levels when administered to diabetic rodents, suggesting it may exhibit the therapeutic characteristics necessary for effective treatment of diabetes. Treatment of animals with FGF21 results in increased energy expenditure, fat utilisation and lipid excretion. FGF21 is most abundantly expressed in the liver, and also expressed in the thymus at lower levels.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Efruxifermin AKR-001; AMG-876; EFX; Fc-FGF21(RGE) Phase 3 Clinical Amgen Inc Non-alcoholic Fatty Liver Disease; Diabetes Mellitus Details
Recombinant human FGF21 Fc fusion protein(Anyuan Pharmaceutical) AP-025 Phase 2 Clinical Anyuan Pharmaceutical Technology (Shanghai) Co Ltd Hypertriglyceridemia; Non-alcoholic Fatty Liver Disease Details
BOS-580 Phase 2 Clinical Novartis Pharma Ag Non-alcoholic Fatty Liver Disease Details
HEC-88473 HEC-88473; HEC88473 Phase 2 Clinical Dongguan Hec Taigen Biopharmaceuticals Co Ltd Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease; Hepatitis; Obesity Details
AP-026 AP-026 Phase 1 Clinical Anyuan Pharmaceutical Technology (Shanghai) Co Ltd Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Obesity; Hyperlipidemias; Overweight Details
YH-25724 YH-25724; YH25724 Phase 1 Clinical Yuhan Corp Non-alcoholic Fatty Liver Disease Details
Pegozafermin BIO89-100; TEV-47948 Phase 3 Clinical 89bio Inc, Teva Hypertriglyceridemia; Non-alcoholic Fatty Liver Disease Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message